Literature DB >> 26597827

Vitamin D-mediated hypercalcemia in multicentric Castleman's disease.

Ken-Ichiro Tanaka1, Ippei Kanazawa2, Hitomi Miyake1, Shozo Yano3, Chika Amano4, Noriyoshi Ishikawa5, Riruke Maruyama5,6, Toshitsugu Sugimoto1.   

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.

Entities:  

Keywords:  25-Hydroxyvitamin D 1-alpha-hydroxylase; Castleman disease; Hypercalcemia; Prednisolone; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 26597827     DOI: 10.1007/s00774-015-0726-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  14 in total

Review 1.  Fifty years of multicentric Castleman's disease.

Authors:  Ashita Waterston; Mark Bower
Journal:  Acta Oncol       Date:  2004       Impact factor: 4.089

2.  Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.

Authors:  Akinori Yuzuriha; Takayuki Saitoh; Hiromi Koiso; Takeki Mitsui; Hideki Uchiumi; Akihiko Yokohama; Hiroshi Handa; Masaru Kojima; Norifumi Tsukamoto; Masamitsu Karaswa; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Acta Haematol       Date:  2011-07-14       Impact factor: 2.195

3.  A case of hypercalcemia associated with Castleman disease.

Authors:  Terri Washington; Avni Vora; Dan Mihailescu
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

4.  Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab).

Authors:  Khalid Ibrahim; Irfan Maghfoor; Assem Elghazaly; Nasir Bakshi; Said Y Mohamed; Mahmoud Aljurf
Journal:  Hematol Oncol Stem Cell Ther       Date:  2011

5.  Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis.

Authors:  N Inui; A Murayama; S Sasaki; T Suda; K Chida; S Kato; H Nakamura
Journal:  Am J Med       Date:  2001-06-15       Impact factor: 4.965

6.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

Review 7.  Multicentric Castleman's disease.

Authors:  B A Peterson; G Frizzera
Journal:  Semin Oncol       Date:  1993-12       Impact factor: 4.929

8.  Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy.

Authors:  Katie N Evans; Harris Taylor; Daniel Zehnder; Mark D Kilby; Judith N Bulmer; Farah Shah; John S Adams; Martin Hewison
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone.

Authors:  S V Reddy; S Takahashi; M Dallas; R E Williams; L Neckers; G D Roodman
Journal:  J Bone Miner Res       Date:  1994-05       Impact factor: 6.741

10.  Calcitriol-mediated hypercalcemia: causes and course in 101 patients.

Authors:  Peter J Donovan; Lana Sundac; Carel J Pretorius; Michael C d'Emden; Donald S A McLeod
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.